Tower Research Capital (TRC)’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-9,111
| Closed | -$31K | – | 4739 |
|
|
2018
Q3 | $31K | Buy |
+9,111
| New | +$32.8K | ﹤0.01% | 2062 |
|
|
2018
Q1 | – | Sell |
-623
| Closed | -$3K | – | 4228 |
|
|
2017
Q4 | $3K | Sell |
623
-9,245
| -94% | -$50.9K | ﹤0.01% | 3153 |
|
|
2017
Q3 | $71K | Buy |
9,868
+7,629
| +341% | +$54.9K | 0.01% | 1676 |
|
|
2017
Q2 | $16K | Buy |
+2,239
| New | +$14K | ﹤0.01% | 1359 |
|
|
2017
Q1 | – | Sell |
-5,911
| Closed | -$35K | – | 4399 |
|
|
2016
Q4 | $35K | Buy |
+5,911
| New | +$32.3K | ﹤0.01% | 1684 |
|
|
2016
Q2 | – | Sell |
-3,430
| Closed | -$16K | – | 5323 |
|
|
2016
Q1 | $16K | Buy |
3,430
+3,200
| +1,391% | +$12.8K | ﹤0.01% | 1536 |
|
|
2015
Q4 | $1K | Sell |
230
-5,034
| -96% | -$23.9K | ﹤0.01% | 4273 |
|
|
2015
Q3 | $19K | Sell |
5,264
-3,359
| -39% | -$22.5K | ﹤0.01% | 1794 |
|
|
2015
Q2 | $86K | Buy |
8,623
+1,701
| +25% | +$18.2K | 0.01% | 968 |
|
|
2015
Q1 | $88K | Buy |
+6,922
| New | +$89K | 0.01% | 1004 |
|
|
2014
Q4 | – | Sell |
-1
| Closed | – | – | 5065 |
|
|
2014
Q3 | $0 | Buy |
+1
| New | +$15 | ﹤0.01% | 5156 |
|
|
2014
Q2 | – | Sell |
-19,984
| Closed | -$341K | – | 4949 |
|
|
2014
Q1 | $341K | Buy |
+19,984
| New | +$302K | 0.04% | 278 |
|
|
2013
Q4 | – | Sell |
-18,426
| Closed | -$186K | – | 5146 |
|
|
2013
Q3 | $186K | Buy |
+18,426
| New | +$164K | 0.02% | 801 |
|
Tower Research Capital (TRC)'s KERX Position: Q4 2018 in Review
Tower Research Capital (TRC) sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 9,111 shares — an estimated $31K sold.
Tower Research Capital (TRC) first reported a position in KERX in Q3 2013 and held it in 13 quarters. The position peaked at $341K in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Tower Research Capital (TRC) reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Tower Research Capital (TRC) sold 9,111 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $31K.
- Tower Research Capital (TRC) first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 13 quarters.
- Tower Research Capital (TRC)'s Keryx Biopharmaceuticals Inc position peaked at $341K in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2018, filed 14 Feb 2019.